Eli Lilly has conducted only initial non-commercial research under its 2024 evaluation agreement with Peptron on the SmartDepot sustained-release microsphere platform, with no verified commercial licensing, technology transfer, or binding deal announced as of mid-August 2026. Recent reporting highlights Lilly's pivot toward alternatives like Camurus for long-acting peptide formulations and ongoing doubts about SmartDepot validation timelines, fueling trader skepticism. With the October 7 resolution date approaching, the absence of concrete milestones or executive statements sustains the 87.5% implied probability on No, though an unexpected announcement in the next eight weeks remains the key swing factor.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật13% khả năng
$11,264 KL.
$11,264 KL.
Oct 7, 2026
13% khả năng
$11,264 KL.
$11,264 KL.
Oct 7, 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly has conducted only initial non-commercial research under its 2024 evaluation agreement with Peptron on the SmartDepot sustained-release microsphere platform, with no verified commercial licensing, technology transfer, or binding deal announced as of mid-August 2026. Recent reporting highlights Lilly's pivot toward alternatives like Camurus for long-acting peptide formulations and ongoing doubts about SmartDepot validation timelines, fueling trader skepticism. With the October 7 resolution date approaching, the absence of concrete milestones or executive statements sustains the 87.5% implied probability on No, though an unexpected announcement in the next eight weeks remains the key swing factor.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Thị trường mở: May 5, 2026, 8:02 PM ET
Khối lượng
$11,264Ngày kết thúc
Oct 7, 2026Thị trường mở
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly has conducted only initial non-commercial research under its 2024 evaluation agreement with Peptron on the SmartDepot sustained-release microsphere platform, with no verified commercial licensing, technology transfer, or binding deal announced as of mid-August 2026. Recent reporting highlights Lilly's pivot toward alternatives like Camurus for long-acting peptide formulations and ongoing doubts about SmartDepot validation timelines, fueling trader skepticism. With the October 7 resolution date approaching, the absence of concrete milestones or executive statements sustains the 87.5% implied probability on No, though an unexpected announcement in the next eight weeks remains the key swing factor.
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Khối lượng
$11,264Ngày kết thúc
Oct 7, 2026Thị trường mở
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly has conducted only initial non-commercial research under its 2024 evaluation agreement with Peptron on the SmartDepot sustained-release microsphere platform, with no verified commercial licensing, technology transfer, or binding deal announced as of mid-August 2026. Recent reporting highlights Lilly's pivot toward alternatives like Camurus for long-acting peptide formulations and ongoing doubts about SmartDepot validation timelines, fueling trader skepticism. With the October 7 resolution date approaching, the absence of concrete milestones or executive statements sustains the 87.5% implied probability on No, though an unexpected announcement in the next eight weeks remains the key swing factor.
Tóm tắt AI thử nghiệm tham chiếu dữ liệu Polymarket. Đây không phải tư vấn giao dịch và không ảnh hưởng đến cách thị trường này được giải quyết. · Cập nhật
Cẩn thận với liên kết bên ngoài.
Cẩn thận với liên kết bên ngoài.
Câu hỏi thường gặp